The strong genetic associations to PD were a driving factor in advancing LRRK2 therapeutics, and this was further facilitated by early findings that the most common pathogenic LRRK2 missense mutations increase the enzyme's catalytic protein kinase activity [14,15]. The gene discussed is LRRK2; the disease is Parkinson disease.